Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

作     者：Renyi Su Xuyong Wei Qiang Wei Di Lu Zuyuan Lin Shuo Wang Chuxiao Shao Xiao Xu 

作者机构：Department of Hepatobiliary and Pancreatic SurgeryAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhouChina NHC Key Laboratory of Combined Multi-Organ TransplantationHangzhouChina Department of Hepatobiliary and Pancreatic SurgeryShu Lan HospitalShu Lan International Medical College of Zhejiang Shuren UniversityHangzhouChina Department of Hepatobiliary and Pancreatic SurgeryAffiliated Lishui HospitalZhejiang University School of MedicineLishuiChina 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第3期

页      面：400-411页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：National Natural Science Funds for Distinguished Young Scholar of China/International(grant No.81625003) National Science and Technology Major Project of China(grant No.2017ZX10203205) Science Funds for Young Scholar of China(grant No.81702858) Youth Program of Natural Science Foundation of Zhejiang Province(grant No.LQ17H160006) 

主　　题：Non-alcoholic fatty liver disease(NAFLD) liver transplant sarcopenia lipid gut 

摘      要：Background and Objective:Non-alcoholic fatty liver disease(NAFLD)is highly prevalent in patients who undergo liver transplantation(LT).Whereas there is huge data on NAFLD,little is known about NAFLD in *** this review,we aim to explore extrahepatic organs and their potential mechanisms in the development of NAFLD in LT patients and discuss current limitations in preclinical and clinical scenarios with suggestions for future ***:The following keywords,such as NAFLD,NASH,liver transplant,therapy,pathogenesis and biomarkers,were set for literature *** articles which were published articles in English till 25th June 2020 in PubMed database were included,and there is no limit for the study design *** Content and Findings:Following LT,there are significant shifts in the microbiota and farnesoid X receptor may be a potential therapeutic target for NAFLD in LT *** roles of probiotics and diet on NALFD remain inconclusive in LT ***,the adipokines and cytokines disorder and local insulin resistance of adipose tissue may contribute to NAFLD *** surgeries are promising in controlling de novo and recurrent NAFLD with significant reduction in abdominal adipose tissue,despite the optimal timing is inconclusive in LT ***,circumstantial evidence indicates that miRNA-33a may function as a mediator bridging sarcopenia and NAFLD of post-LT.β-Hydroxy-β-Methyl-Butyrate treatment could improve muscle status in graft recipients and shows protective potential for NAFLD in LT ***:Gut,adipose tissue and muscle are intricately intertwined in promoting NAFLD in LT *** animal studies are needed to deepen our understanding of mechanisms in multi-organ *** quality clinical trials are warrant for making guidelines and developing management strategies on NAFLD after LT.